DK3297656T3 - Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili - Google Patents
Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili Download PDFInfo
- Publication number
- DK3297656T3 DK3297656T3 DK16723776.7T DK16723776T DK3297656T3 DK 3297656 T3 DK3297656 T3 DK 3297656T3 DK 16723776 T DK16723776 T DK 16723776T DK 3297656 T3 DK3297656 T3 DK 3297656T3
- Authority
- DK
- Denmark
- Prior art keywords
- haemophilia
- treatment
- von willebrand
- willebrand factor
- factor polypeptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15168930 | 2015-05-22 | ||
| EP16163239 | 2016-03-31 | ||
| PCT/EP2016/061443 WO2016188907A1 (en) | 2015-05-22 | 2016-05-20 | Truncated von willebrand factor polypeptides for treating hemophilia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3297656T3 true DK3297656T3 (da) | 2020-03-09 |
Family
ID=56024318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16723776.7T DK3297656T3 (da) | 2015-05-22 | 2016-05-20 | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10688157B2 (da) |
| EP (1) | EP3297656B1 (da) |
| JP (1) | JP6573989B2 (da) |
| KR (1) | KR20180006453A (da) |
| CN (1) | CN107787328B (da) |
| AU (1) | AU2016266627A1 (da) |
| BR (1) | BR112017023785A2 (da) |
| CA (1) | CA2986626A1 (da) |
| DK (1) | DK3297656T3 (da) |
| ES (1) | ES2774011T3 (da) |
| HK (1) | HK1250625A1 (da) |
| IL (1) | IL255652A (da) |
| MX (1) | MX2017014503A (da) |
| RU (1) | RU2017145014A (da) |
| SG (2) | SG11201708755WA (da) |
| TW (1) | TW201713685A (da) |
| WO (1) | WO2016188907A1 (da) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3538133T3 (da) * | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| DK3641800T5 (da) | 2017-06-22 | 2024-08-26 | CSL Behring Lengnau AG | Modulation af fviii immunogenicitet ved trunkeret vwf |
| EP3728287B1 (en) | 2017-12-19 | 2024-04-10 | CSL Behring Lengnau AG | Protein purification and virus inactivation with alkyl glycosides |
| TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療ａ型血友病的方法 |
| CN110950964B (zh) * | 2018-09-26 | 2021-06-18 | 安源医药科技（上海）有限公司 | 突变型单链人凝血因子viii融合蛋白及其制备方法与用途 |
| CN114072420B (zh) * | 2019-07-04 | 2024-06-11 | 康诺贝林伦瑙有限公司 | 用于增加凝血因子viii的体外稳定性的截短的血管性血友病因子(vwf) |
| WO2024200652A1 (en) * | 2023-03-31 | 2024-10-03 | Octapharma Ag | Fviii-vwf fusion proteins with improved pharmacokinetics |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| DE69534265T2 (de) | 1994-12-12 | 2006-05-04 | Beth Israel Deaconess Medical Center, Inc., Boston | Chimäre zytokine und ihre verwendung |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| CA2252896C (en) | 1996-04-24 | 2009-03-10 | The Regents Of The University Of Michigan | Inactivation resistant factor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| ES2233036T3 (es) | 1998-04-27 | 2005-06-01 | Opperbas Holding B.V. | Composicion farmaceutica que comprende factor viii y liposomas neutros. |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| CA2434097A1 (en) | 2001-01-12 | 2002-08-08 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor viii |
| WO2002103024A2 (en) | 2001-06-14 | 2002-12-27 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
| US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
| ATE463514T1 (de) | 2002-04-29 | 2010-04-15 | Sanquin Bloedvoorziening | ANTAGONISTEN DER INTERAKTION ZWISCHEN FAKTOR VIII UND LRP (ßLOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEINß) |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| CA2517369C (en) | 2003-02-26 | 2013-06-04 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| ATE497783T1 (de) | 2003-05-06 | 2011-02-15 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| KR100758755B1 (ko) | 2003-06-12 | 2007-09-14 | 일라이 릴리 앤드 캄파니 | Ｇｌｐ-1 유사체 융합 단백질 |
| KR20060124656A (ko) | 2003-12-31 | 2006-12-05 | 메르크 파텐트 게엠베하 | 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질 |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| SI3130601T1 (sl) | 2004-11-12 | 2020-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| AU2005322067B8 (en) | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| DE102005002444A1 (de) | 2005-01-19 | 2006-07-27 | Wella Ag | Behälter mit einem Ventil |
| EP1874815A1 (en) | 2005-04-14 | 2008-01-09 | CSL Behring GmbH | Modified coagulation factor viii with enhanced stability and its derivates |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2010222A1 (en) | 2006-03-31 | 2009-01-07 | Baxter International Inc. | Pegylated factor viii |
| ES2910207T3 (es) | 2006-06-14 | 2022-05-11 | Csl Behring Gmbh | Proteínas de fusión escindibles proteolíticamente que comprenden un factor de coagulación de la sangre |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| ES2392569T3 (es) * | 2007-06-13 | 2012-12-11 | Csl Behring Gmbh | Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| JP5876416B2 (ja) | 2009-11-13 | 2016-03-02 | グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | フォンウィルブランド因子（ｖＷＦ）含有調製品並びにこれに関連する方法、キット及び使用 |
| MX347519B (es) * | 2011-06-17 | 2017-04-28 | Berry Plastics Corp | Depósito aislado. |
| WO2013093760A2 (en) | 2011-12-19 | 2013-06-27 | Grifols, S.A. | Compositions, methods, and kits for preparing sialylated recombinant proteins |
| ES2753124T3 (es) | 2012-01-12 | 2020-04-07 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos de factor VIII y usos de los mismos |
| PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
| CN104411716B (zh) * | 2012-04-24 | 2018-09-07 | 诺和诺德股份有限公司 | 适用于治疗血友病的化合物 |
| EP2662083A1 (en) * | 2012-05-08 | 2013-11-13 | CSL Behring GmbH | Sugar compositions for treating hemophilia a and/or von willebrand disease |
| LT2882450T (lt) * | 2012-07-11 | 2020-03-25 | Bioverativ Therapeutics Inc. | Faktoriaus viii komplekso su xten ir von vilebrando faktoriumi baltymas ir jo panaudojimas |
| WO2014198699A2 (en) | 2013-06-12 | 2014-12-18 | Novo Nordisk A/S | Compounds suitable for treatment of haemophilia |
| RS63583B1 (sr) | 2014-01-10 | 2022-10-31 | Bioverativ Therapeutics Inc | Himerni proteini faktora viii i njihova upotreba |
-
2016
- 2016-05-20 DK DK16723776.7T patent/DK3297656T3/da active
- 2016-05-20 MX MX2017014503A patent/MX2017014503A/es unknown
- 2016-05-20 CN CN201680029650.6A patent/CN107787328B/zh active Active
- 2016-05-20 SG SG11201708755WA patent/SG11201708755WA/en unknown
- 2016-05-20 JP JP2017560682A patent/JP6573989B2/ja not_active Expired - Fee Related
- 2016-05-20 KR KR1020177037156A patent/KR20180006453A/ko unknown
- 2016-05-20 ES ES16723776T patent/ES2774011T3/es active Active
- 2016-05-20 RU RU2017145014A patent/RU2017145014A/ru not_active Application Discontinuation
- 2016-05-20 BR BR112017023785-7A patent/BR112017023785A2/pt not_active Application Discontinuation
- 2016-05-20 EP EP16723776.7A patent/EP3297656B1/en active Active
- 2016-05-20 WO PCT/EP2016/061443 patent/WO2016188907A1/en active Application Filing
- 2016-05-20 US US15/576,055 patent/US10688157B2/en active Active
- 2016-05-20 SG SG10201910896UA patent/SG10201910896UA/en unknown
- 2016-05-20 CA CA2986626A patent/CA2986626A1/en not_active Abandoned
- 2016-05-20 AU AU2016266627A patent/AU2016266627A1/en not_active Abandoned
- 2016-05-23 TW TW105116001A patent/TW201713685A/zh unknown
-
2017
- 2017-11-14 IL IL255652A patent/IL255652A/en unknown
-
2018
- 2018-08-02 HK HK18109996.5A patent/HK1250625A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180006453A (ko) | 2018-01-17 |
| WO2016188907A1 (en) | 2016-12-01 |
| SG11201708755WA (en) | 2017-12-28 |
| JP6573989B2 (ja) | 2019-09-11 |
| US10688157B2 (en) | 2020-06-23 |
| JP2018517691A (ja) | 2018-07-05 |
| CA2986626A1 (en) | 2016-12-01 |
| SG10201910896UA (en) | 2020-01-30 |
| RU2017145014A (ru) | 2019-06-24 |
| US20180161402A1 (en) | 2018-06-14 |
| CN107787328B (zh) | 2021-08-06 |
| IL255652A (en) | 2018-01-31 |
| MX2017014503A (es) | 2018-08-01 |
| AU2016266627A1 (en) | 2018-01-18 |
| HK1250625A1 (zh) | 2019-01-11 |
| CN107787328A (zh) | 2018-03-09 |
| BR112017023785A2 (pt) | 2018-07-17 |
| ES2774011T3 (es) | 2020-07-16 |
| EP3297656A1 (en) | 2018-03-28 |
| EP3297656B1 (en) | 2020-01-08 |
| TW201713685A (en) | 2017-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3297656T3 (da) | Trunkeret von Willebrand Faktor polypeptider til behandling af hæmofili | |
| DK3556775T3 (da) | Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter | |
| DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| HK1256525A1 (zh) | 突變的截短的von willebrand因子 | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK2976359T4 (da) | Fremgangsmåder til behandling af osteogenesis imperfecta | |
| DK3400238T3 (da) | Muteret von willebrand faktor | |
| DK3164150T3 (da) | Modificeret von willebrand-faktor | |
| DK3152230T3 (da) | Præparat omfattende faktor viii og von willebrand-faktor-peptider | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| DK3618845T3 (da) | Peptider til behandling af diabetes | |
| DK3478713T3 (da) | Sammensætninger til behandling af amyloidose | |
| HK1250724A1 (zh) | 用於製備經修飾的血管性血友病因子的方法 | |
| DK3538133T3 (da) | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili | |
| DK3394089T3 (da) | Polypeptider til inhibering af komplementaktivering | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom | |
| HK1244292A1 (zh) | 具有改善的半衰期的經修飾的血管性血友病因子 | |
| DK3641800T3 (da) | Modulation af fviii immunogenicitet ved trunkeret vwf | |
| DK3525942T3 (da) | Skiferryster | |
| DK3183359T3 (da) | Effektiv valg af rekombinante proteiner | |
| DK3558381T3 (da) | Flydende sammensætning på basis af humant fibrinogen | |
| DK3265489T3 (da) | Forbindelser til forbedring af halveringstiden af von willebrand faktor |